Studies have shown that active fund managers routinely underperform the S&P500 index*​

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

REGN Stock Predictions and Ratings

WSX Rating:
STRONG BUY
WSX Forecast (1yr):
26%
Analyst Rating:
BUY
Analyst Forecast (1yr):
28.80%

REGN Stock Analysis

REGN PE Ratio: 15.1

REGN PEG Ratio: 0.8

REGN Forward EPS Growth (12 month): 19.00%

REGN PS Ratio: 4.3

REGN PSG Ratio: 0.4

REGN Forward Revenue Growth (12 month): 11.00%

REGN Articles

No data was found